Leronlimab for Alzheimer's Disease and Mild Cognitive Impairment
This study is testing a drug called leronlimab in 20 participants who have Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. You must be 50 years or older and have biomarker-confirmed MCI/AD to join. While leronlimab has been studied for other conditions like HIV and certain cancers, this is the first time its safety and effect on brain inflammation will be tested in people with AD or MCI. The main goal is to see if leronlimab is safe and if it changes levels of brain inflammation. This study is not currently recruiting, as its status is unclear.
- Study design
- This is an interventional study with 20 participants. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Brain inflammation will be measured at the beginning of the study and again at Week 13.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Tracy A Butler, MD · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Mean change from baseline in whole-brain inflammation using 11C-DPA-713 Positron Emission Tomography (PET)Baseline; Week 13
The primary outcome measure is leronlimab's effect on brain inflammation using a PET tracer that measures translocator protein (TSPO) activation on microglia.